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Summary: Between January 1987 and January 1991, 168 known HIV-infected prisoners have 
been incarcerated in Dublin’s Mountjoy prison. This figure constitutes 16.6% of the total HIV-
infected population in the Republic of Ireland over the same period. One hundred and forty-one 
(84%) of these prisoners have attended the Department of Genitourinary Medicine, St James’s 
Hospital, Dublin. This group displayed considerable morbidity from HIV-related disease. 
Respiratory tract infection was the most frequent complication seen. Much additional morbidity 
was directly attributable to intravenous drug use. A survey of a representative group of inmates 
revealed that 64.7% were diagnosed HIV-positive in prison. The mean length of time spent 
incarcerated since the diagnosis of HIV infection was 38.9 months. Twenty-nine of 34 individuals 
who answered a questionnaire were imprisoned for drug-related crimes and 32 of 34 prisoners 
admitted to parenteral drug use within the prison. As the HIV epidemic unfolds in Dublin, 
increasing numbers of prisoners with symptomatic HIV disease will spend time incarcerated in 
Mountjoy prison. This will pose a considerable burden on prison and hospital medical services 
alike. 
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Introduction 
HIV infection and AIDS has posed unprecedented 
problems for prison authorities worldwide. A survey 
performed on behalf of the Council of Europe found the 
prevalence of HIV infection, among prisoners in 
Western Europe unusually high in relation to the general 
population1. In Italy and Spain where mandatory 
screening of new inmates is practised, HIV prevalence 
rates of 16.8% and 26% respectively have been 
reported1. 
 The first known HIV-infected prisoner in an Irish 
‘prison was identified in 1985. However, there is a 
paucity of information on the impact that HIV infection 
has had on the Irish prison service and, in particular, on 
the prison medical service. Prisoners known to be 
infected with HIV are held in Mountjoy prison, north 
Dublin, which is one of the country’s largest closed 
correctional institutions. Since 1986 the prison has 
operated a segregation policy for male inmates who are 
identified as being HIV seropositive. Up to 42 prisoners 
are incarcerated in the separation unit. HIV-infected 
female prisoners (approximately 4 at any time) are 
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held in Mountjoy’s women’s prison, but are not 
segregated from other female prisoners. 
 As there is no compulsory screening for HIV, the 
prevalence of HIV infection in the general prison 
population of approximately 600 inmates is unknown. 
However, indirect evidence suggests that the actual 
number of HIV-infected prisoners in Mountjoy prison 
could be considerably greater than officially recognized. 
Up to 25% of offenders admitted to Mountjoy prison 
have a history of intravenous drug use2 and 
seroprevalence of HIV among Dublin’s intravenous 
drug users has been estimated to be anything between 
15% and 50%3. 
 Since January 1987 the medical care of HIV-
infected inmates in Mountjoy prison has been 
coordinated between the prison medical service and the 
Department of Genitourinary Medicine at St James’s 
Hospital. Prisoners regularly attend the outpatient HIV 
clinic for clinical assessment and monitoring of their 
HIV disease. Direct admission to hospital for HIV-
related illness is arranged, when necessary, between the 
prison medical service and the genitourinary medical 
team. Most prisoners continue to attend for monitoring 
of their HIV disease on release from prison. The aim of 
this study was to examine in detail the demographic, 
clinical and custodial profiles of a cohort of HIV 
infected 
individuals who have been incarcerated in Mountjoy 
prison over a 4-year period. 
SUBJECTS AND METHODS 
All known HIV seropositive prisoners incarcerated in 
Mountjoy prison between January 1987 and January 
1991 were identified from prison medical records. 
These were cross-referenced with the medical register at 
the Department of Genitourinary Medicine, St James’s 
Hospital. Case notes were reviewed for demographic 
information, risk factor for H1V acquisition, and current 
clinical staging of H1V disease4. To assess the pattern 
of HIV-related disease and morbidity, both as inmates 
and when released, case notes were reviewed for 
clinical episodes requiring evaluation, treatment, 
admission to hospital or specialist referral. Particular 
note was made of other communicable diseases 
including hepatitis B, pulmonary tuberculosis and 
sexually transmitted diseases (STDs). The cause of 
death, if known, was documented. 
 To obtain a profile of custodial care, and to 
establish the pattern of injecting drug practices among 
HIV-infected prisoners in the segregation unit, a 
voluntary and confidential structured 
interview/questionnaire, was carried out on inmates 
over a 2-week period in January 1991. The reason(s) for 
imprisonment, current sentence, the number of prison 
terms, year and place of diagnosis of H1V infection and 
total length of time incarcerated in the segregation unit 
since, diagnosis of H1V infection were documented. 
Inmates were questioned for details of intravenous drug 
use, including age of commencement, and whether they 
had injected drugs within the prison. 
RESULTS 
Demographic 
Over the 4-year period between January 1987 and 
January 1991, 168 (157 male, 11 female) known HIV-
positive prisoners have been incarcerated in Mountjoy 
prison. Of these, 141 (83.9%; 134 male, 7 female) have 
attended the Department of Genitourinary Medicine in 
St James’s Hospital for management of their H1V 
disease. The mean age of this group was 28.8 years 
(range 19-43). Intravenous drug use was the 
predominant risk factor identified for the acquisition of 
H1V (138/141, 97.8%). 
Clinical 
Of the 141 current or ex-prisoners who attended 5t 
James’s Hospital, 58 (41.1%) were classified as CDC 
group It, 54 (38.3%) as CDC group III and 29 (20.6%) 
CDC group IV H1V disease. Figure 1 summarizes the 
major diagnostic categories of clinical problems (total 
229) identified in this population over the 4-year period. 
Pulmonary, gastrointestinal, and dermatological 
conditions constituted the commonest 
 
clinical problem documented. Bacterial lower 
respiratory tract infection was the single most common 
condition seen. More detailed analysis of these 229 
clinical episodes revealed that considerable morbidity 
was directly attributable to intravenous drug use (skin 
sepsis/abscess 22, hepatitis 6, peripheral arterial 
occlusion 2 and femoral vein thrombosis 2, drug 
overdose 2, bacterial endocarditis 2, and one case of 
Fournier’s gangrene of scrotum). Mycobacterium 
tuberculosis infection was identified in 6 individuals 
(pulmonary in 3 and extrapulmonary in 3). There was 
evidence of previous exposure to hepatitis B in 92 
(65.2%) individuals. Eighty-six (60.9%) had anti-
heptitis B core IgG ab and 6 (4.25%) were HBs Ag 
and/or HBe Ag positive. In 13 (9.2%) individuals 
serological markers for hepatitis B were negative and 
the remaining 29 (20.6%) were untested. Sexually 
transmitted infections were identified in 20 individuals 
of whom 17 had genital warts. 
 There were 14 direct admissions from prison to 
St James’s Hospital for HIV-related problems. Six had 
CDC stage IV disease. Bacterial lower respiratory tract 
infection was the commonest reason for admission 
(4/14). Two inmates were admitted with Pneumocystis 
carinii pneumonia (PCP), one of whom was from the 
main prison block, and was only subsequently 
diagnosed H1V seropositive on admission to hospital. 
 A total of 12 deaths occurred in the study 
population. Five of the 12 had early H1V disease (CDC 
stage II/III). Three of the deaths occurred whilst in 
custody; one each from suicide, drug overdose and PCP. 
One died shortly following 
Table 1. Custodial profile of a group of male inmates 
(n=34) in the segregation unit of Mountjoy prison 
 Mean Median Range 
Age (years) 28.2 27.5 21-40 
Current sentence (months) — 42 8-life 
Current sentence served 
(months) 
21.3 11 1-144 
Number of prison terms 3 — 1-8 
January 1986 to January 1991 
Total length incarcerated 38.9 38 6-60 
January 1986 to January 1991 
(months) 
compassionate release to hospital for treatment of 
Fournier’s gangrene. 
Custodial 
Thirty-four out of a group of 38 prisoners in the 
segregation unit completed the questionnaire/ interview 
on details of their custody and sentencing. Two were 
remand prisoners. Table 1 outlines the custodial details 
of this group. Twenty-nine (85.2%) were imprisoned for 
drug-related crimes. All but two had used drugs 
intravenously prior to current term of imprisonment. 
Two inmates claimed to have commenced injecting 
drug use during current sentence and one other inmate 
had commenced using intravenous drugs during a 
previous term of imprisonment. Thirty-two (94%) 
admitted to continued intravenous drug use within the 
prison. The mean length of time of diagnosis of HIV 
infection was 3.7 years (range 6 months to 5 years) and 
22 (64.7%) had been HIV-positive for more than 4 
years. Twenty-two (64.7%) had been diagnosed HIV 
seropositive within the Irish prison system. The 
distribution of the clinical staging of HIV disease in this 
subgroup of inmates was similar to that of the study 
population as a whole; 22 (64.7%) were clinically 
classified as CDC group II disease, 11 (32.3%) CDC 
group III disease and 5 (14.7%) group IV disease. 
DISCUSSION 
Although the WHO’S special programme on AIDS has 
laid down policy guidelines for the management of 
HIV-infected prisoners5, there is no clear consensus of 
approach. Several studies have addressed the issues of 
prevalence and transmission of HIV within prison 
institutions6-10. However, few studies have detailed the 
actual or potential clinical burden of HIV disease, with 
perhaps the exception of tuberculosis11,12, on prison and 
allied medical services. We have attempted to detail the 
pattern of clinical disease and custodial profile of a 
cohort of HIV-infected prisoners (ex and current) in 
Ireland. 
 Between January 1987 and January 1991, 168 
known HIV-infected prisoners were incarcerated in 
Mountjoy prison. This figure represents an 
astonishing 16.6%, of the total number of cases of HIV 
infection reported in the Republic of Ireland over the 
same period13. Although the study population comprised 
both current and ex-inmates, evidence suggests that the 
spectrum of clinical conditions seen are a valid 
representation of those that occur in any given group of 
HIV-infected inmates held in custody in Mountjoy 
prison. Firstly, the distribution of clinical staging of 
HIV disease in the subgroup of inmates studied were 
similar to that of the whole population. Secondly, as is 
seen from their custodial pattern, many prisoners are re-
offenders, and frequently alternate between periods of 
imprisonment and release. 
 Although 20.6% of the study population were 
clinically classified as having symptomatic HIV disease 
(CDC stage IV) at the end of the study period, there 
appeared to be a disproportionate level of morbidity 
among the group as a whole. The pattern of HIV disease 
is similar to that previously reported in an Irish 
population14. Respiratory tract infection, particularly 
bacterial, was the commonest clinical problem 
identified. However, despite reports of an increased 
frequency of pulmonary tuberculosis in HIV-infected 
prison inmates11’12, it was diagnosed in only 3 
individuals in this study, none of whom was in custody 
at the time of diagnosis. 
 There was considerable morbidity related to 
intravenous drug use. The large number of cases of skin 
sepsis and abscess formation due to the use of 
contaminated needles were not only seen in ex-inmates 
but also in prisoners in custody. This would suggest that 
significant parenteral drug misuse occurs within 
Mountjoy prison, a suspicion supported by the findings 
of the survey of inmates. Several studies have already 
highlighted the extent of drug misuse and needle sharing 
in prisons worldwide6-8,15. All but two prisoners in our 
survey had a history of injecting illicit drugs prior to 
their current term of imprisonment. The inference from 
this data is that these two individuals probably became 
infected with HIV through needle sharing following 
incarceration. Ninety-four per cent of those surveyed in 
this study continued to inject drugs whilst in prison. 
Assuming that the pattern of drug use is not dissimilar 
among intravenous drug users in the main prison body, 
there is considerable potential for transmission of HIV, 
particularly as inmates are unlikely to have exclusive 
access to their own injecting equipment. 
 Not surprisingly psychiatric morbidity, e.g. 
depression, was common in the study population. There 
are a wide variety of psychiatric conditions recognized 
in individuals with HIV infection and AIDS16, many of 
which are likely to be exacerbated by incarceration in 
prison. Three of the 12 deaths were as a result of suicide 
and/or drug overdose and two of these occurred in 
custody. Psychiatric illness among inmates is a major 
determinant of prison suicide17. In addition to adequate 
medical facilities and services, there is a need for ready 
access to 
comprehensive psychiatric and counselling services 
which may play an important role in attempts to reduce 
rates of prison suicides18. 
 No information was sought on prisoners’ sexual 
practices either within or outside prison. Other studies 
have highlighted sexual risk behaviour and potential for 
sexual transmission of HIV in prisons6’9. However, the 
high prevalence of sexually-acquired infections in this 
group is a source of concern. It lends support to reports 
that intravenous drug users in Dublin are failing to 
adopt safe sex practices19. The potential risk of 
transmission of HIV to partners in the community once 
released from prison deserves recognition. 
 More detailed study of custodial patterns of 
HIV-infected inmates revealed that many have spent 
considerable periods in custody. Of those prisoners 
surveyed/ the mean total length of time (38.9 months) 
spent in custody over the 5-year period since the 
establishment of the segregation unit in Mountjoy, was 
considerably greater than that of a population of 
intravenous drug users who had served custodial 
sentences in a London prison7. Significantly, most were 
re-offenders with a mean number of prison terms of 3. 
The reasons for this are varied. Existing drug treatment 
services are inadequate to deal with Dublin’s large 
population of intravenous drug users, estimated to be 
around 70003, necessitating continued involvement in 
crime to support their addiction. Moreover, illicit 
intravenous drug use in Ireland is concentrated mainly 
in Dublin and active users are unlikely to move outside 
this jurisdiction. It is not surprising, therefore, that 65% 
of those inmates surveyed had been HIV seropositive 
for greater than 4 years. Assuming that this pattern 
continues, one can expect an increasing burden on the 
prison medical services from inmates with symptomatic 
and advanced HIV disease. 
 This study has highlighted a number of 
important points relating to the burden of HIV disease 
on an Irish prison population. A substantial proportion 
of Ireland’s total HIV-infected population have spent 
time in custody in Mountjoy prison. Given the 
prevalence of HIV infection among Dublin’s drug users 
and the number of offenders that use intravenous drugs, 
the true prevalence of HIV infection among inmates is 
probably greater than officially recognized. Much of the 
morbidity, and indeed mortality, of this population was 
drug related. As the HIV epidemic among Dublin’s drug 
users progresses, and considering their custodial pattern, 
increasing numbers of HIV-infected 
prisoners with symptomatic and advanced HIV disease 
will be incarcerated. This will further stretch a prison 
medical service already ill-equipped to deal with a 
problem of this scale. It is clear that considerable 
medical and financial resources need to be devoted to 
the management of HIV disease in Irish prisons. 
Acknowledgements: We thank Mountjoy Prison 
Administration and the Irish Department of Justice for 
their assistance. 
References 
1 Harding TW. AIDS in prison. Lancet 1987;ii:1260-3 
2 O’Mahony P. Abstinence in treated and untreated opiate 
abusers: a study of a prison sample. Ir J Psychol Med 
1990;7:121-3 
3 O’Kelly F, Bury G, Carey O. Policy statement on illicit 
drug use and problems of drug addiction. Ir Coll Gen 
Pract 1989 
4 Centre for Disease Control. Revision of the CDC 
surveillance case definition fur acquired immune 
deficiency syndrome. MMWR 1987;36(suppl 1s):3s-15s 
5 WHO consultation on prevention and control of AIDS 
in prisons. Lancet 1987; ii: 1263-4 
6 Carvell ALM, Hart GJ. Risk behaviours for HIV 
infection among drug users in prison. BMJ 
1990:300:1383-4 
7 Dye S, Isaacs C. Intravenous drug misuse among prison 
inmates: implications for spread of HIV. BMJ 
1991;302:1506 
8 Gaughwin MD, Douglas RM, Liew C, et al. HIV 
prevalence and risk behaviours for HIV transmission in 
South Australian prisons. AIDS 1991; 5:845-51 
9 Power KG, Markova I, Rowlands A, et al. Sexual 
behaviour in Scottish prisons. BMJ 1991; 302:1507-8 
10 Brewer TF, Vlahov D, Taylor E, et al. Transmission of 
HIV-1 within a statewide prison system. AIDS 
1988;ii:363-7 
11 Darbyshire JH. Tuberculosis in prisons. BMJ 
1989;299:874 
12 Snider DE, Hutton MD. Tuberculosis in correctional 
institutions. JAMA 1989:261:436-7 
13 Department of Health AIDS statistics, Dublin, January 
1991 
14 Murphy M, Misquito N, Pomeroy L, et at. Admissions 
for HIV related disease in a Dublin hospital 1987-1990. 
Int J STD AIDS 1991;2:436-9 
15 Kennedy DH, Nair G, Elliot L, Ditton J. Drug misuse 
and sharing of needles in Scottish prisons. BMJ 
1991;302:1507 
16 Maj M- Psychiatric aspects of HIV-1 infection and 
AIDS. Psychol Med 1990; 20:547-63 
17 Dooley E. Prison suicide in England and Wales, 1972-
87. Br J Psychiatry 1990; 156:40-5 
18 Skegg K, Cox B. Impact of psychiatric services on 
prison suicide. Lancet 1991:338:1436-8 
19 Pomeroy L, O’Connor J, Joseph B. Needle sharing and 
sexual behaviour amongst attenders at a methadone 
maintenance programme in Dublin. VII International 
Conference on AIDS, Florence, June 1991 (abstract) 
(Accepted 13 August 1992) 
